Our findings indicate that Jun copy number loss might, therefore, represent a useful biomarker for entinostat resistance in luminal breast cancer where these Jun-deleted patients might be suggested to not receive entinostat containing regimens. This evidence concerns the gene JUN and breast carcinoma.